SAMHD1 mutations in mantle cell lymphoma are recurrent and confer in vitro resistance to nucleoside analogues

Marco M Bühler; Junyan Lu; Sebastian Scheinost; Ferran Nadeu; Damien Roos-Weil; Manfred Hensel; Tharshika Thavayogarajah; Holger Moch; Markus G Manz; Eugenia Haralambieva; Ewerton Marques Maggio; Sílvia Beà; Eva Giné; Elías Campo; Olivier A Bernard; Wolfgang Huber; Thorsten Zenz

doi:10.1016/j.leukres.2021.106608

SAMHD1 mutations in mantle cell lymphoma are recurrent and confer in vitro resistance to nucleoside analogues

Leuk Res. 2021 Aug:107:106608. doi: 10.1016/j.leukres.2021.106608. Epub 2021 May 3.

Authors

Marco M Bühler¹, Junyan Lu², Sebastian Scheinost³, Ferran Nadeu⁴, Damien Roos-Weil⁵, Manfred Hensel⁶, Tharshika Thavayogarajah⁷, Holger Moch⁸, Markus G Manz⁷, Eugenia Haralambieva⁸, Ewerton Marques Maggio⁸, Sílvia Beà⁹, Eva Giné¹⁰, Elías Campo⁹, Olivier A Bernard⁵, Wolfgang Huber¹¹, Thorsten Zenz¹²

Affiliations

¹ Department of Pathology and Molecular Pathology, University Hospital and University of Zurich, Zurich, Switzerland; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Hematopathology Section, Laboratory of Pathology, Hospital Clínic de Barcelona, University of Barcelona, Barcelona, Spain.
² European Molecular Biology Laboratory (EMBL), Heidelberg, Germany.
³ Molecular Therapy in Hematology and Oncology, National Center for Tumor Diseases, German Cancer Research Center (DKFZ), Heidelberg, Germany.
⁴ Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Centro de Investigación Biomédica en Red de Cancer (CIBERONC), Madrid, Spain.
⁵ Gustave Roussy, INSERM U1170, Villejuif and Université Paris-Saclay Orsay, France.
⁶ Mannheim Oncology Practice, Mannheim, Germany.
⁷ Department of Medical Oncology and Hematology, University Hospital and University of Zurich, Zurich, Switzerland.
⁸ Department of Pathology and Molecular Pathology, University Hospital and University of Zurich, Zurich, Switzerland.
⁹ Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Hematopathology Section, Laboratory of Pathology, Hospital Clínic de Barcelona, University of Barcelona, Barcelona, Spain; Centro de Investigación Biomédica en Red de Cancer (CIBERONC), Madrid, Spain.
¹⁰ Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Centro de Investigación Biomédica en Red de Cancer (CIBERONC), Madrid, Spain; Department of Hematology, Hospital Clínic de Barcelona, University of Barcelona, Barcelona, Spain.
¹¹ European Molecular Biology Laboratory (EMBL), Heidelberg, Germany; Molecular Medicine Partnership Unit (MMPU), Heidelberg, Germany.
¹² Department of Medical Oncology and Hematology, University Hospital and University of Zurich, Zurich, Switzerland. Electronic address: thorsten.zenz@usz.ch.

PMID: 33979727
DOI: 10.1016/j.leukres.2021.106608

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Antineoplastic Agents / pharmacology
Drug Resistance, Neoplasm / genetics*
Humans
Lymphoma, Mantle-Cell / drug therapy
Lymphoma, Mantle-Cell / genetics*
Lymphoma, Mantle-Cell / pathology*
Mutation*
Nucleosides / analogs & derivatives
Nucleosides / pharmacology
Recurrence
SAM Domain and HD Domain-Containing Protein 1 / genetics*

Substances

Antineoplastic Agents
Nucleosides
SAM Domain and HD Domain-Containing Protein 1
SAMHD1 protein, human